Arax Advisory Partners
FLNA icon

Arax Advisory Partners’s Filana Therapeutics FLNA Stock Holding History

Arax Advisory Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-368
Closed -$680 – 5259
2026
Q1 		$680 Sell
368
-77
-17% -$159 ﹤0.01% 3370
2025
Q4 		$882 Hold
445
– – ﹤0.01% 3516
2025
Q3 		$1.29K Hold
445
– – ﹤0.01% 3200
2025
Q2 		$806 Hold
445
– – ﹤0.01% 2850
2025
Q1 		$668 Buy
+445
New +$1.12K ﹤0.01% 2463

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Arax Advisory Partners's FLNA Position: Q2 2026 in Review

Arax Advisory Partners sold out of Filana Therapeutics (FLNA) in Q2 2026, closing a stake of 368 shares — an estimated $680 sold.

Arax Advisory Partners first reported a position in FLNA in Q1 2025 and held it in 5 quarters. The position peaked at $1.29K in Q3 2025. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Arax Advisory Partners reported no remaining Filana Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 368 Filana Therapeutics shares in Q2 2026, an estimated $680.
  • Arax Advisory Partners first reported a position in Filana Therapeutics in Q1 2025 and held it in 5 quarters.
  • Arax Advisory Partners's Filana Therapeutics position peaked at $1.29K in Q3 2025.
  • 85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.